Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA
Crossref DOI link: https://doi.org/10.1038/s41392-024-01770-y
Published Online: 2024-02-20
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zheng, Lang
Wang, Wenjing
Sun, Qiu http://orcid.org/0000-0001-5122-2226
Text and Data Mining valid from 2024-02-20
Version of Record valid from 2024-02-20
Article History
Received: 2 February 2024
Accepted: 6 February 2024
First Online: 20 February 2024
Competing interests
: The authors declare no competing interests.